Crescita Therapeutics Inc. specializes in dermatology, offering both non-prescription skincare and prescription drug products. Key strengths include a solid gross margin of 46.9% and a healthy liquidity position, indicated by a current ratio of 2.80. However, concerns arise from negative EBITDA and net margins, suggesting operational challenges. While the gross margin is strong, the overall financial health is undermined by low profitability and a market cap of only $14.71M, indicating potential undervaluation or investor skepticism.
Loading financial metrics...
No significant red flags identified
This company appears financially healthy on available metrics
Exceptional revenue growth of 28.1% YoY demonstrates strong market demand and competitive positioning.
Operating margin expanded by 14.6pp, demonstrating strong operational leverage.
Both gross margin (+2.4pp) and operating margin (+14.6pp) are expanding simultaneously, indicating the company is scaling profitably.
Strong gross margin of 51.7% reflects healthy unit economics.
Fortress balance sheet: cash covers total debt 3.5×, providing significant financial flexibility.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2026-Q1 (March 31, 2026)